TRT Found to Reduce Anemia in Hypogonadal Men
After 54 weeks of treatment with testosterone undecanoate, anemia prevalence decreased from 29.6% to 10%.
After 54 weeks of treatment with testosterone undecanoate, anemia prevalence decreased from 29.6% to 10%.
Study also identifies clinical characteristics associated with testosterone deficiency in this population.
73% of men in the testosterone group showed improvement in sexual arousal, interest, and drive.
Larger studies and long-term follow-up needed to determine possible risks of treatment.
Serum total and free testosterone declined in men on hemodialysis who received a 6-month course of the drug for secondary hyperparathyroidism.
Increased odds of low testosterone with opioid exposure; increased odds with increasing age, comorbidities.
The study found no association with obesity, however, unlike previous studies.
A recent review found little evidence to support severe lower urinary tract symptoms as a contraindication to TRT.
A new study by University of Pennsylvania and Stanford researchers highlights a possible link between men who receive androgen deprivation therapy (ADT) and the future onset of Alzheimer’s disease.
Increased insulin sensitivity in men with type 2 diabetes and hypogonadotropic hypogonadism.